Lv2
130 积分 2025-10-27 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
13天前
已完结
需要Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide文件补充材料
1个月前
已完结
胰腺癌新型系统治疗药物研究、应用现状及进展
5个月前
已完结
皖公网安备34019202002308
